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Abstract Multiple mass spectra (MS1 to MS6) of 55
phenylalkylamine derivatives were recorded with ion-trap
mass spectrometry employing electrospray (ESI) and
atmospheric pressure chemical ionization (APCI). Frag-
mentation patterns were studied in detail and a generally
applicable scheme was established for elucidation of the
structures of phenylalkylamine derivatives. HPLC com-
bined with ion-trap multiple mass spectrometry was used
to identify the structure of reaction by-products in ecstasy
samples from the “black” market. Low nanogram amounts
were sufficient for on-line HPLC–MSn structure elucida-
tion of unknowns.
Keywords Designer drugs · Dimethoxyamphetamine ·
LC–MSn · MDMA · Phenethylamines ·
Trimethoxyamphetamine
Introduction
During the last five years LC–MS has become a widely
used tool for the analysis of thermally labile and/or polar
molecules. The introduction of LC–MS ion-trap instru-
ments in 1996 enabled a structure elucidation with low
nanogram amounts. These instruments enable on-line gen-
eration of a consecutive series of product-ion spectra by
sequential isolation/fragmentation of selected ions, result-
ing in a series of MS2, MS3 to MSn spectra, which contain
highly structure-significant information. However, so far
no general rules have been established for elucidation of a
structure from the observed fragments, as for electron-im-
pact ionization. Therefore, our group has started to develop
structure-elucidation schemes for different compound
classes such as carbonyl-dinitrophenylhydrazones [1, 2],
trichothecenes [3], aconite alkaloids [4], or oligomers of
bisphenol A diglycidyl ether [5].
Many important neurotransmitters such as dopamine,
adrenaline, or noradrenalin and synthetic drugs such as dex-
amine, amphecloral, fenfluramine, orthoxine, or methoxy-
phenamine contain the phenethylamine (1-phenyl-2-
ethanamine, Fig. 1, 1a) or amphetamine (1-phenyl-2-
propanamine, Fig. 1, 1b) substructure. Mescaline (3,4,5-
trimethoxy-phenethylamine, Fig. 2, 13a) is also the active
compound in different species of cactus regarded as most
sacred by the native American culture. The effects on hu-
mans have been investigated for more than 150 phenyl-
alkylamines [6]. The structures of the 55 phenylalkyl-
amine derivatives studied in this work are shown in Figs. 1
and 2.
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Fig. 1 Structures of the unsubstituted, monomethoxy- and methyl-
enedioxyphenylalkylamines investigated
Phenylalkylamine derivatives attract considerable pub-
lic attention, since the US food and drug administration
(FDA) has classified N-methyl-3,4-methylendioxyamphet-
amine (MDMA, Fig. 1, 6c) as a most restricted Class 1
compound in 1985–86. MDMA is the main representative
of a class of pharmacologically active compounds called
empathogens. Dosages of 50 to 100 mg MDMA induce a
state of increased empathy, and feelings of centeredness
and inner peace [7]. Empathogens continue to be suggested
as potential therapeutic agents in facilitating psychother-
apy [8]. Considerable benefits and few undesirable side
effects have been reported from restricted medical use in
Switzerland during the period 1989–1993 [9], and strong
anti-Parkinson effects were described recently [10]. How-
ever, long-term abuse of high dosages of illicit ecstasy
seems to be related to increased depression and reduced
short-term memory [11].
Although MDMA is regarded as relatively safe (Refs.
[12, 13] and Bernhard Meili, Bundesamt f. Gesundheits-
wesen, Bern, Switzerland; personal communication), re-
lated designer drugs PMA (4-methoxyamphetamine, Fig. 1,
4b), PMMA (N-methyl-4-methoxyamphetamine), and 
4-MTA (4-methylthioamphetamine) have caused several
casualties during recent years [14, 15, 16]. In addition,
other compounds such as 2C-B (Fig. 2, 16a), 2C-I (Fig. 2,
17), 2C-T2 (Fig. 2, 18), 2C-T7 (Fig. 2, 19), TMA-2 (Fig. 2,
14b) and TMA-6 (Fig. 2, 15b) have been identified in pills
sold in Switzerland (unpublished results). Moreover, new
illicit psychoactive phenylalkylamine derivatives are ex-
pected to appear on the market which might not have the
effect of MDMA [17]. This can then lead to overdose af-
ter attempts to reach the expected state and, consequently,
increase the risk of acute damage or even death.
More than one hundred articles about the analysis of
MDMA-related compounds have been published during
the past five years [18, 19]. However, none describe rapid
and reliable elucidation of the structure of completely un-
known phenylalkylamine derivatives. Detailed investiga-
tions of methoxyphenyl [14, 20] and methylendioxyphenyl
compounds [21, 22, 23] revealed that retention time and
EI or CI mass spectra of isomers often are identical. There-
fore, elucidation of the structure of closely related ana-
logues remains tricky and time-consuming. Recently pub-
lished examples are N-methyl-1-phenethylamine [24],
PMMA [25], 4-MTA [26], and 2C-B (4-bromo-2,5-di-
methoxyphenylethylamine) [27].
The aim of this work was to study the possibility of us-
ing multiple mass spectrometry (MSn) techniques to iden-
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Fig. 2 Structures of the dimethoxy-,
trimethoxy-, and further substituted
phenylalkylamines investigated
tify rapidly and unequivocally unknown and/or new de-
signer drugs in pills. The MS1 to MS4 fragmentation of
model compounds is described in detail and their impor-
tance for structure elucidation discussed. Finally, the po-
tential of the identification scheme was tested by elucidat-
ing the structure of impurities in pills.
Experimental
Chemicals
Benzaldehyde, 2-methoxybenzaldehyde, 3-methoxybenzaldehyde,
4-methoxybenzaldehyde, 2,3-methylendioxybenzaldehyde, 3,4-meth-
ylendioxybenzaldehyde, 2,3-dimethoxybenzaldehyde, 2,4-dimeth-
oxybenzaldehyde, 2,5-dimethoxybenzaldehyde, 3,4-dimethoxy-
benzaldehyde, 3,5-dimethoxybenzaldehyde, 2,3,4-trimethoxybenz-
aldehyde, 2,4,5-trimethoxybenzaldehyde, 2,4,6-trimethoxybenzal-
dehyde, and 3,4,5-trimethoxybenzaldehyde were purchased from
Fluka (Buchs, Switzerland). All compounds were of “purum” qual-
ity (97–98%).
Nitromethane (puriss., 98.5%), nitroethane (pract. 90–95%), 
1-nitropropane (pract. 90–95%), acetic acid (puriss.), ammonium
acetate (puriss., 99%) n-butylamine (purum, 97%), LiAlH4 (pu-
rum, 97%), and tetrahydrofuran (THF, puriss. absolute over mo-
lecular sieve) were purchased from Fluka (Buchs, Switzerland).
Ultrapure water was from a Elga Maxima HLPC water supply sys-
tem (Elga, High Wycombe, Bucks, UK). Methanol of “pesticide
residue analysis” grade was purchased from sds (Peypin, France),
and dichloromethane was from Romil (Cambridge, England).
Synthesis of reference compounds
Most reference compounds were synthesized with the general
method given in Ref. [6]. The method was modified for micro
amounts. The aldehyde (10 mg) was added to a mixture of 8 mg ni-
tromethane, 1 mg acetic acid, and 1 mg n-butylamine (catalyst) in
a 5-mL vial. The reaction mixture was heated for 1–3 h at 75 °C
until the color was deep-yellow. After cooling to room tempera-
ture, 1 mL H2O was added. The formed yellow nitrostyrene was
extracted with 1.5 mL CH2Cl2. The organic layer was separated
and evaporated to dryness. Sometimes the residual yellow oil crys-
tallized spontaneously.
The nitrostyrenes were reduced to the corresponding phenethyl-
amines as follows. The nitrostyrene (approx. 1 mg) was dissolved
in 0.5 mL dry THF in a 1-mL vial, and 5 mg LiAlH4 was added.
The vial was closed air-tight and the reaction mixture was left for
1–2 h at 40 °C to form the phenethylamine. After cooling, 1–3 drops
H2O containing 10% of ammonium acetate were added to destroy
hydride residues. The reaction mixture was transferred to a 5-mL
Teflon syringe equipped with a 0.45-µm (25 mm i.d.) nylon filter
(Scientific Resources, Eatontown NJ, USA) and a few more milli-
liters of water were added. After filtration the reaction mixture was
diluted approximately tenfold with a 50:50 mixture of CH3OH and
H2O containing 1% ammonium acetate. This solution was injected
directly into the mass spectrometer. The purity of the synthetic
product was usually 80–90%. The most abundant impurity was the
corresponding N-hydroxystyrene. Nitromethane was replaced by
nitroethane for synthesis of amphetamines, and by 1-nitropropane
for 1-phenyl-2-butane amines.
Mass spectrometry
All reference mass spectra were recorded with a ThermoFinnigan
LCQ-G2 ion-trap mass spectrometer equipped with electrospray
(ESI) or atmospheric pressure chemical ionization (APCI) ion
sources. Solutions containing 10–100 ng µL–1 of phenylalkylamine
derivatives in 50:50 CH3OH–H2O were injected with the syringe
pump at a flow rate of 5 µL min–1. MS settings were: spray voltage,
4.5 kV; heated capillary temperature, 150 °C; capillary voltage 47 V,
tube-lens offset –5 V, octapole 1 offset –3 V, lens voltage –16 V,
octapole 2 offset –5 V, multipole RF amplitude 400 V, automatic
gain control on, full MS target 5×107. The scan range was usually
50–500 u; isolation width, 1.4 u (MS2, isolation efficiency 99.9%
for the 12C peak) or 2 u (MS3 to MS6). Collision-induced dissocia-
tion (CID) was carried out at 22% (MS2) or 30% trap energy (MS3
to MS6).
Analysis of pills
Compounds in pills were determined by coupling a Rheos 2000
HPLC pump (flux instruments, Basel, Switzerland) and a PAL au-
tosampler (CTC Analytics, Zwingen, Switzerland) in front of the
mass spectrometer. The pill was dissolved in 100 mL water, acidi-
fied with one drop conc. HCl, by ultrasonication for 5 min. A few
milliliters of the resulting solution were filtered though a 0.45-µm
(25 mm i.d.) nylon filter (Scientific Resources, Eatontown NJ,
USA). Filtrate (50 µL) was transferred to a 5-mL vial and 4.95 g
water (acidified with a few drops HCl per liter) was added. The re-
sulting drug concentration was in the range 1–15 ng µL–1. HPLC
separation was performed on a Nucleosil HD C18 phase (125 mm
length, 3 mm i.d., 3 µm particle size, 120 Å pore size; Macherey–
Nagel, Oensingen, Switzerland). Elution was performed with a
gradient prepared from 50 mmol L–1 ammonium acetate (solvent A)
and methanol (solvent B, pesticide grade, sds, Peypin, France) at a
flow rate of 500 µL min–1. The gradient was: 0 min (70% A, 30% B),
2 min (70% A, 30% B), 25 min (20% A, 80% B), 26 min (70% A,
30% B), 30 min (70% A, 30% B).
Results and discussion
Selection and synthesis of reference compounds
From the literature [6, 28] it was concluded that future
phenylalkylamines introduced on the black market will be
substituted mainly at three positions, at the amino group
(R1 in Fig. 1), at the carbon atom α to the amino group
(R2 in Fig. 1) and at the aromatic ring. Substituents at the
amino group are usually –H, –CH3, –CH2CH3, and –(CH3)2,
and at the α carbon atom –H, –CH3, or –CH2CH3. Numer-
ous substituents are introduced into the aromatic ring. Most
common are –H, –OCH3, and –O–CH2–O– (methylene-
dioxy) groups in different combinations, but also –CH3,
–CH2CH3, –OCH2CH3, –SCH3, –SCH2CH3, –Cl, –Br, –I,
and others are described in the literature [6, 17, 26, 28,
29].
The corresponding phenethylamines, amphetamines and
1-phenyl-2-butane amines were synthesized from 15 com-
mercially available aldehydes as described in the experi-
mental section. Nine deuterium-labeled compounds were
also prepared. Labeling of both the carbon skeleton and
the nitrogen was necessary to identify clearly the origin of
fragments in the MSn spectra. In addition, eleven phenyl-
alkylamine derivatives were donated by a variety of insti-
tutions. A complete list of all the compounds studied is
given in Figs. 1 and 2.
Recording of reference spectra
More than 300 MSn spectra were recorded from 19 phen-
ethylamines, 20 amphetamines, and 16 1-phenyl-2-bu-
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Fig. 3 Principal MSn fragmentation
behavior of phenethylamines (left),
amphetamines (middle) and 1-phenyl-
2-butanamines (right)
Fig. 4 MS2 spectra of 
3,4-methylenedioxyampheta-
mine (MDA, top; loss of NH3),
N-methyl-3,4-methylene-
dioxyamphetamine (MDMA,
middle; loss of CH3NH2), and
N-ethyl-3,4-methylenedioxy-
amphetamine (MDE, bottom;
loss of CH3CH2NH2). Scan se-
quence: [M+H]+→scan
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tanamines. Amounts of 10 ng were sufficient for record-
ing MS–MS or MSn spectra when injected with the sy-
ringe pump. The information from the recorded MS1 to
MS4 spectra can be summarized as follows (see also Fig. 3).
MS spectra
ESI and APCI spectra recorded in the positive-ion mode
contained a pronounced [M+H]+ peak for all compounds,
enabling determination of the molecular mass. The maxi-
mum temperature of the heated capillary should not ex-
ceed 180–200 °C, however, otherwise, thermal degrada-
tion occurs, resulting in reduced abundance of [M+H]+.
Typical isotope signals also enabled identification of het-
ero atoms such as S, Cl, or Br.
MS2 spectra
In this step the amino function is lost together with its
substituents, forming [M+H–NH2R]+, which is always the
base peak. Other fragments have a relative intensity of <5%.
Therefore, N-substitution of an unknown can be identified
directly from the MS2 spectrum. Loss of 17 u (NH3) is
typical for primary amines, loss of 31 u (H2N–CH3) for
N-methylated compounds, and loss of 45 u for N-ethyl-
ated or N,N-dimethylated compounds. MS2 spectra of 
3,4-methylendioxyamphetamine (MDA), N-methyl-3,4-
methylenedioxyamphetamine (MDMA), and N-ethyl-3,4-
methylenedioxyamphetamine (MDE) are given in Fig. 4
as examples. As expected, the MS3 spectra of the formed
m/z 163 ion are identical for MDA, MDMA, and MDE.
MS3 spectra
MS3 spectra enable determination of the substitution at the
α carbon atom, because of fragmentation of the saturated
side-chain (see Fig. 5 for typical spectra). Consequently,
1-phenyl-2-butanamines lose 42 u (C3H6), amphetamines
28 u (C2H4), and phenethylamines 15 u (CH3). For 1-phenyl-
2-butane amines the [M+H–NH2R–C3H6]+ ion formed is
always the base peak, and other ions have relative abun-
dances of <30%. For amphetamines [M+H–NH2R–C2H4]+
is most abundant, but [M+H–NH2R–15]+ also often has
high intensity.
[M+H–NH2R–15]+ is usually the base peak for phen-
ethylamines. It is often accompanied by a pronounced
[M+H–NH2R–30]+ ion. Peak intensity of [M+H–NH2R–28]+
Fig. 5 Typical MS3 spectra of
phenethylamines (top, loss of
15 u); amphetamines (middle,
loss of 28 u), and (2-amino-
butyl)benzenes (bottom, loss 
of 42 u). Here the MS3 spectra
of the 3,4,5-trimethoxy-
compounds are shown. 
Scan sequence:
[M+H]+→[M+H–NH3]+→scan
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Fig. 6 MS4 spectra of
monomethoxyamphetamines
(top) and 1-(methylene-
dioxyphenyl)-2-butanamines
(bottom). Scan sequence:
[M+H]+→[M+H–NH3]+→
[M+H–NH3–C2H4]+→scan 
(for amphetamines) and
[M+H]+→[M+H–NH3]+→
[M+H–NH3–C3H6]+→scan 
(for 1-phenyl-2-butanamines)
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Fig. 7 MS4 spectra of di-
methoxyamphetamines (a) and
trimethoxyamphetamines (b).
Scan sequence:
[M+H]+→[M+H–NH3]+→
[M+H–NH3–C2H4]+→scan.
The strange fragments at
m/z 139 (for dimethoxyam-
phetamines) or m/z 169 
(for trimethoxyamphetamines)
probably result from addition
of water to m/z 121 or m/z 151,
respectively
and [M+H–NH2R–42]+ is <10%, which therefore enables
differentiation of phenethylamine derivatives from 1-phenyl-
2-butanamines and amphetamines. Deuterium-labeling
showed that the [M+H–NH2R–15]+ ion is formed both by
cleavage of the ethyl C–C bond and loss of –CH3 from a
methoxy group.
MS4 spectra
MS4 fragmentation formed the C7H6+ radical ion (for phen-
ethylamines) or the benzylium ion (amphetamines and 
1-phenyl-2-butanamines; Fig. 3). The resulting fingerprint
spectra contain detailed information about aromatic ring
substitution. This is especially useful for di- and trisubsti-
tuted compounds and enables identification of different
isomers:
– Methoxy-substitution at the 2- and 4-positions gives
identical MS4 spectra (Fig. 6) but the 3-position is dis-
tinguishable.
– 2,3- or 3,4-methylendioxy-substitution results in identi-
cal MS4 spectra (Fig. 6) but differentiation by use of the
MS3 spectra is possible.
– The MS4 spectra of 2,3-, 2,4-, 2,5-, 3,4-, and 3,5-di-
methoxy isomers are all different (Fig. 7).
– The same is valid for 2,3,4-, 2,4,5-, 2,4,6-, and 3,4,5-tri-
methoxy-compounds (Fig. 7).
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Fig. 7b
– Other studied substitution patterns such as 4-bromo-
2,5-dimethoxy-, 4-iodo-2,5-dimethoxy-, 2,5-dimethoxy-
4-methyl-, and 4-propylthio-2,5-dimethoxy- also gener-
ated different MS4 spectra.
Some phenethylamines are indistinguishable in the MS4,
MS5, and MS6 spectra. Examples are the pairs 2,3- and
3,4-dimethoxyphenethylamine, 2,4- and 3,5-dimethoxy-
phenethylamine, and 2,3,4- and 3,4,5-trimethoxyphen-
ethylamine.
Moreover, some MS4 spectra revealed the formation of
ion molecule adducts with H2O. It seems that their forma-
tion is indicative of two methoxy groups in the meta posi-
tion. The mechanism of formation was not studied further,
however [2, 30].
Structure elucidation scheme
A generally applicable structure elucidation scheme was
developed on the basis of the recorded MS (see Fig. 8). It
enables step-by-step elucidation of the structure of un-
known phenylalkylamines. The molecular mass and the
presence of hetero atoms such as Cl, Br, and S can be easily
determined by MS. The fragments formed during MS2 give
information about N-substitution, whereas the α-C-substi-
tution can be derived from MS3 spectra. Information about
aromatic ring substitution is part of the “fingerprint patterns”
in the MS4 to MS6 spectra and requires comparison with
reference spectra of the corresponding positions. If no ref-
erence spectrum matches the unknown the structure can of-
ten be derived from the combined MS1 to MS6 information.
Reproducibility
MS–MS spectra and those of higher order (MS3–MS6)
were highly reproducible. Of course, the relative intensities
of the precursor and product ions was influenced by chang-
ing the experimental conditions (collision energy, colli-
sion gas pressure, software). However, the relative inten-
sity of product ions vary within a few percent only even
over several years and between different LCQ instruments
and different software.
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Fig. 8 Scheme for elucidation of the
structure of unknown phenylalkyl-
amines by means of multiple mass
spectrometry (MSn)
A change of ion-trap pressure (helium, cooling gas) is
much less critical than for triple quadrupole instruments
(argon collision gas), because the ion-trap collision en-
ergy is normally applied to the mass of the selected pre-
cursor ion only.
Application to unknowns
Elucidation of the structure of two impurities was per-
formed by means of the selective fragmentation processes
described above to demonstrate the applicability of the
approach. The mass spectra obtained from one example
are given in Fig. 9. A by-product present in an illicit
MDMA sample furnished an [M+H]+ ion at m/z 210. Loss
of 31 u (m/z 179), typical of an N-methylated compound,
was observed in the MS2 spectrum. The base peak in the
MS3 spectrum was m/z 151 (loss of 28 u) and identified
the compound as an amphetamine derivative. The MS4
fingerprint was identical to the MS4 fingerprint of 3,4-di-
methoxyamphetamine, revealing the overall structure was
N-methyl-3,4-dimethoxyamphetamine.
In a sample of 4-bromo-2,5-dimethoxyphenethylamine
(2C-B, 16a in Fig. 2) the following impurities were identi-
fied in a similar manner: N-hydroxy-4-bromo-2,5-di-
methoxyphenethylamine (HPLC signal intensity approx.
0.05%), 2,5-dimethoxyphenethylamine (intensity approx.
0.5%), two different dibromo-dimethoxyphenethylamines
(intensity 0.2% each) and a second bromodimethoxy-
phenethylamine (intensity 0.3%). A compound with [M+H]+
at m/z 246 was also found; this could be 4-bromo-2-hy-
droxy-5-methoxyphenethylamine or 4-bromo-5-hydroxy-
2-methoxyphenethylamine.
Conclusion
The highly structure-selective fragmentations described
enable nearly unequivocal elucidation of the structures of
unknown designer drugs by multiple mass spectrometry.
Amounts of 10 ng are usually sufficient for recording of
interpretable spectra down to MS6. The method is, there-
fore, at least two orders of magnitude more sensitive than
NMR, and only very simple sample pretreatment is neces-
sary. Analysis and data interpretation leading to the struc-
ture of a compound is possible within 15 min after some
training. This study also indicates that structure elucida-
tion and quantification of primary drug metabolites (e.g.
glucuronide and sulfate conjugates) and very polar neuro-
transmitters might be possible with low nanogram amounts.
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Fig. 9 MS2 to MS4 spectra 
of an impurity, identified as
N-methyl-3,4-dimethoxyam-
phetamine, in an illicit MDMA
sample. Because the spectra of
this compound were recorded
with prototype LCQ software
several years ago, the intensi-
ties of the precursor ion peaks
are different from those in the
reference spectra
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